The number of discontinuations due to treatment-related AEs was 13.8%, and treatment-related events, such as increased ALT or AST concentration, hyperlipemia, nausea, proteinuria, decreased appetite, rash, diarrhea, and asthenia (events that typically occur following treatment), were observed in more than 10% of participants. The gene discussed is GPT; the disease is asthenia.